10 September 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced the initiation of a Phase IIb clinical trial of Bicifadine - a serotonin and norepinephrine reuptake inhibitor (SNRI) - for the treatment of diabetic neuropathic pain... XTL Biopharmaceuticals' Press Release -
Showing posts with label XTL Biopharmaceuticals. Show all posts
Showing posts with label XTL Biopharmaceuticals. Show all posts
Tuesday, September 11, 2007
XTL Biopharmaceuticals , Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10 September 2007 - XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced the initiation of a Phase IIb clinical trial of Bicifadine - a serotonin and norepinephrine reuptake inhibitor (SNRI) - for the treatment of diabetic neuropathic pain... XTL Biopharmaceuticals' Press Release -
Subscribe to:
Posts (Atom)
